Navigation Links
Cellular Biomedicine Group Announces Expansion in the Osteoarthritis and Rheumatoid Arthritis Market
Date:6/13/2013

PALO ALTO, Calif., June 13, 2013 /PRNewswire/ -- Cellular Biomedicine Group, Inc. (OTCQB: CBMG), a biomedicine firm engaged in the development of new treatments for degenerative and cancerous diseases, today announced their anticipation of expansion in the China Osteoarthritis and Rheumatoid Arthritis market. A complete analysis of current China patents by an intellectual property law firm has rendered the legal opinion that Cellular Biomedicine Group has complete freedom of IP operation with regards to their patents for autologous and allogeneic adipose-derived stem cell compositions for the treatment of osteoarthritis and rheumatoid arthritis, as well as for various stem cell processing and preservation technologies.

Dr. Wei (William) Cao, President of Cellular Biomedicine Group, commented, "In China there are 72.5 Million people suffering from Knee Osteoarthritis (KOA), and 4.5 Million suffering from Rheumatoid Arthritis (RA). We are very confident to enter the world's largest KOA and RA market with freedom of operation."

About Cellular Biomedicine Group
Cellular Biomedicine Group, Inc. develops proprietary cell therapies for the treatment of certain degenerative diseases and cancers.  Our developmental stem cell, progenitor cell, and immune cell projects are the result of research and development by scientists and doctors from China and the United States. Our flagship GMP facility, consisting of eight independent cell production lines, is designed, certified and managed according to U.S. standards.  To learn more about CBMG, please visit:www.cellbiomedgroup.com

Forward-Looking Statements
Statements in this press release relating to plans, strategies, trends, specific activities or investments, and other statements that are not descriptions of historical facts may be forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking information is inherently subject to risks and uncertainties, and actual results could differ materially from those currently anticipated due to a number of factors, which include, but are not limited to, risk factors inherent in doing business. Forward-looking statements may be identified by terms such as "may," "will," "expects," "plans," "intends," "estimates," "potential," or "continue," or similar terms or the negative of these terms. Although CBMG believes the expectations reflected in the forward-looking statements are reasonable, they cannot guarantee that future results, levels of activity, performance or achievements will be obtained. CBMG does not have any obligation to update these forward-looking statements other than as required by law.

Contact:
Jeff Ramson 
Investor Relations
ProActive Capital Group
+1 646-863-6341

Sarah Kelly 
Director of Corporate Communications, CBMG
+1 650 566 5064
sarah.kelly@cellbiomedgroup.com


'/>"/>
SOURCE Cellular Biomedicine Group, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Cellular Therapy and Cord Blood 2013 Market Report
2. Cellular Biomedicine Group Announces Appointment of Corporate Controller
3. Cellular Dynamics International Expands MyCell Products Line with Disease Models, Genetic Engineering Patents
4. Cellular Dynamics International Files Registration Statement for Proposed Initial Public Offering
5. Cellular Biomedicine Group Achieves 50% Enrollment Milestone in Phase I Clinical Trial for Knee Osteoarthritis
6. Intra-Cellular Therapies Appoints Professor Sir Michael Rawlins to its Board of Directors
7. Top Genetic and Cellular Researchers Honored at ASGCT 16th Annual Meeting
8. Exit discovered in cellular garbage truck
9. ASGCT Annual Meeting to Highlight Latest Advances in Genetic and Cellular Therapeutics
10. Cellular Biomedicine Group Provides Update and 2013 Milestones
11. Unique Extracellular Matrix Used in Patient Successfully Treated for Flesh Eating Bacteria
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/7/2018)... ... 2018 , ... The Discovery on Target (DOT) conference in ... preeminent event on novel drug targets.” BellBrook Labs’ high throughput screening (HTS) platforms, ... targets in a quest to find new treatments for disease. , BellBrook Labs ...
(Date:9/1/2018)... ... 2018 , ... Rudina Thanasi, a scientifically validated holistic energy ... treated nutraceutical supplement used in combating inflammation and autoimmune disorders. , ... as, organ-specific inflammation. The reported data is as follows: , More than ...
(Date:8/29/2018)... ... 28, 2018 , ... Cognition Corporation ®, a software company specializing in ... NAVIGATE2018 . , Ryan Ward, Director of Engineering at Zimmer Biomet, has been ... engineer and manager with Zimmer Biomet for almost 15 years, Mr. Ward will focus ...
(Date:8/29/2018)... Calif. (PRWEB) , ... August 28, 2018 , ... ... firm for the life sciences and healthcare industries, announces that Manu Vohra will deliver ... August 30th. , What: “How to Implement Box for GxP in 30 Days” ...
Breaking Biology Technology:
(Date:8/26/2018)... ... August 24, 2018 , ... ... diagnostic laboratories. However, this technology introduces many well-described challenges around data processing, ... the South London NHS Genomic Medicine Centre. The Viapath Genetics Laboratories have ...
(Date:8/23/2018)... FREDERICK, Md. (PRWEB) , ... August 22, 2018 ... ... the pending release of LimitLIS® 4.0, the latest version of its rapidly growing ... toxicology labs, LimitLIS® Toxicology Edition, as well as the company’s triple digit growth ...
(Date:8/21/2018)... ... August 21, 2018 , ... Whether it be ... is dedicated to offering customers a successful experience. When browsing the new ... transition between products, with relevant details such as technical manuals, application notes, and ...
Breaking Biology News(10 mins):